Adjuvant ipilimumab in stage III melanoma: New landscape, new questions

European Journal of Cancer

Volumn 69, Issue , 2016, Pages 39-42

  Eggermont, Alexander M M ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Adjuvant therapy; Ipilimumab; Melanoma; Randomised trials; Survival

Indexed keywords

ALPHA INTERFERON; IPILIMUMAB; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); HUMAN; MELANOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; LYMPH NODE DISSECTION; PATHOLOGY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; CTLA-4 ANTIGEN; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LYMPH NODE EXCISION; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 84994236251     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.10.009     Document Type: Article

References (25)

1. [1] Eggermont, A.M.M., Spatz, A., Robert, C., Cutaneous melanoma. Lancet 383 (2014), 816–827.
2. [2] Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27 (2009), 6199–6206.
3. [3] Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Ding, S., Byrd, D.R., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28 (2010), 2452–2459.
4. [4] van der Ploeg, A.P., van Akkooi, A.C., Schmitz, P.I., Koljenovic, S., Verhoef, C., Eggermont, A.M., EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam criteria. Eur J Cancer 46 (2010), 2414–2421.
5. [5] van Akkooi, A.C., Nowecki, Z.I., Voit, C., Schäfer-Hesterberg, G., Michej, W., de Wilt, J.H., et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248 (2008), 949–955.
6. [6] van der Ploeg, A.P., van Akkooi, A.C., Rutkowski, P., Nowecki, Z.I., Michej, W., Mitra, A., et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29 (2011), 2206–2214.
7. [7] van der Ploeg, A.P., van Akkooi, A.C., Haydu, L.E., Scolyer, R.A., Murali, R., Verhoef, C., et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. Eur J Cancer 50 (2014), 111–120.
8. [8] Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C., Blum, R.H., Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:1 (1996 Jan), 7–17.
9. [9] Eggermont, A.M., Suciu, S., Santinami, M., Testori, A., Kruit, W.H., Marsden, J., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372 (2008), 117–126.
10. [10] Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., Suciu, S., Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29 (2003), 241–252.
11. [11] Mocellin, S., Pasquali, S., Rossi, C.R., Nitti, D., Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102 (2010), 493–501.
12. [12] Suciu, S., Ives, N., Eggermont, A.M., Kirwood, J.M., Lorigan, P., Markovic, S., et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). J Clin Oncol, 32(5s), 2014 abstract 9067.
13. [13] Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – update 2016. Eur J Cancer 63 (2016), 201–217.
14. [14] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
15. [15] Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
16. [16] Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
17. [17] Ascierto, P.A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance Fernandez, M., et al. Overall survival and safety results from a phase 3 trial of ipilimumab at 3 mg/kg vs. 10 mg/kg in patients with metastatic melanoma. Ann Oncol, 27(Suppl. 6), 2016 abstract1106O.
18. [18] Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:5 (2015 May), 522–530.
19. [19] Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Prolonged survival with Ipilimumab as adjuvant in stage III melanoma. N Engl J Med, 2016;Oct 7.
20. [20] Coens, S., Suciu, S., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., et al. Phase III trial (EORTC 18071/CA184–029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results. Lancet Oncol, 2016 [in press].
21. [21] Leiter, U., Stadler, R., Mauch, C., Hohenberger, W., Brockmeyer, N., Berking, C., et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:6 (2016 Jun), 757–767.
22. [22] Eggermont, A.M., Suciu, S., MacKie, R., Ruka, W., Testori, A., Kruit, W., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366 (2005), 1189–1196.
23. [23] Eggermont, A.M., Suciu, S., Rutkowski, P., Kruit, W.H., Punt, C.J., Dummer, R., et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 55 (2016 Mar), 111–121.
24. [24] Eggermont, A.M., Suciu, S., Testori, A., Santinami, M., Kruit, W.H., Marsden, J., et al. Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30 (2012), 3810–3818.
25. [25] Eggermont, A.M., Suciu, S., Testori, A., Kruit, W.H., Marsden, J., Punt, C.J., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48 (2012), 218–225.